ArticleCureus2025
Venous Thromboembolism Risk Assessment and Prophylaxis: An Audit-Based Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVenous thromboembolism (VTE), mainly deep vein thrombosis (DVT) and pulmonary embolism (PE), persists as a critical contributor to hospital-acquired mortality. Despite its largely preventable nature, early 2024 data from Bon Secours Hospital in Cork revealed alarmingly low compliance with VTE prophylaxis protocol.
aimThis study evaluated the implementation efficacy of VTE risk assessment and prophylaxis in adult hospitalised patients at Bon Secours Hospital, Cork, according to National Institute for Health and Care Excellence (NICE) guidelines. METHODOLOGY: Adult patients (127) at increased risk of VTE, specifically individuals aged ≥60 years, patients undergoing major surgical procedures, and/or patients with comorbidities including active cancer, hypertension, diabetes, immunological disorders, immobility or haematological disorders, across nine wards were included in this study. We also checked for any kind of bleeding risk, like active bleeding or low platelets. Each point was given 1 mark if present, which added to increase risk of VTE. We analysed the data to check the compliance with accurate prescription and completeness of the forms according to the NICE guideline. Exclusion criteria included paediatric, gynaecological, day-case admissions, and discharges within 24 hours of admission. The incomplete/inaccurate risk assessments were reported to improve timely and correct prophylaxis prescription. Results: Compliance surged with assessment completion, reaching 111 out of 127 (87.39%) with prescription accuracy. Timely assessments within 24 hours accounted for 101 (79.52%), yet 16 (12.64%) remained unassessed. A substantial proportion (103, 80.23%) exhibited one or more VTE risk factors, predominantly advanced age and multiple comorbidities. Anticoagulants, particularly tinzaparin, constituted the principal prophylactic measure, with mechanical prophylaxis employed in only 15 (11.81%). Alarmingly, 22 (17.32%) of high-risk individuals were not prescribed any form of prophylaxis.
conclusionThis study underscores the transformative impact of enforced protocol adherence and targeted multidisciplinary staff education on VTE prevention. The integration of an electronic health record system with real-time prompts could further ensure prophylaxis within the critical 24-hour window.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.